Neurocognitive Impairment, Delirium, Esophageal Cancer, Head and Neck Cancer, Lung Cancer
Conditions
Keywords
delirium, cognitive/functional effects, hypopharyngeal cancer, laryngeal cancer, lip and oral cavity cancer, metastatic squamous neck cancer with occult primary, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus and nasal cavity cancer, salivary gland cancer, esophageal cancer, non-small cell lung cancer, small cell lung cancer
Brief summary
RATIONALE: Gathering information about how often problems with neurocognitive functioning occur in patients with newly diagnosed upper aerodigestive tract cancers may help doctors learn more about the disease. PURPOSE: This clinical trial is studying neurocognitive functioning in patients with newly diagnosed upper aerodigestive tract cancers receiving treatment at Henry-Joyce Cancer Clinic.
Detailed description
OBJECTIVES: Primary * To establish an estimate of the prevalence of baseline neurocognitive impairment prior to initiation of outpatient cancer treatment. * To establish an estimate of the incidence of neurocognitive impairment during outpatient cancer treatment. * To describe how neurocognitive functioning changes over time during cancer treatment. Secondary * To identify sociodemographic and clinical factors associated with neurocognitive impairment. * To examine health-related outcomes associated with neurocognitive impairment. OUTLINE: Patients undergo interview to complete measures of domain-specific neurocognitive functioning, global neurocognitive functioning, subjective neurocognitive functioning, delirium, physical functioning, symptom prevalence and distress, mood states, and medications at baseline before initiation of cancer treatment, at scheduled treatment visits, and at the follow-up visit 3 months after completion of cancer treatment. Measures of comorbidity, alcohol use, sensory functioning (vision and hearing), and sociodemographic are completed at baseline only. Cancer-related information (diagnosis, staging, and sites of metastasis, if applicable), treatment-related information (planned treatment regimen - chemotherapy and/or radiation therapy), and current medications are obtained at baseline by medical record review. Health service use and complications are assessed at each scheduled treatment visit and at the 3-month post-treatment follow-up visit. Measures of domain-specific neurocognitive functioning, coping, and quality of life are completed at baseline and at the 3-month follow-up visit.
Interventions
OTHERAssessment of therapy complications
Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
OTHERQuality-of-life assessment
Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
Sponsors
National Cancer Institute (NCI)
Vanderbilt University Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Newly diagnosed solid tumors of the upper aerodigestive system, including cancers of the head and neck, esophagus, or lung * Receiving treatment at the Henry-Joyce Cancer Clinic at the Vanderbilt-Ingram Cancer Center * No known brain metastasis PATIENT CHARACTERISTICS: * Able to hear, speak, and understand English * No prior diagnosis of other cancer except basal cell carcinoma PRIOR CONCURRENT THERAPY: * No treatment plans including prophylactic cranial irradiation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Domain-Specific Neurocognitive Functioning measuring attention, executive functioning, mental processing speed, verbal memory, language, and visuospatial construction at baseline and 3 months after completion of treatment | Baseline and 3 months post-treatment |
| Global neurocognitive functioning as measured by the Mini-Mental State Examination (MMSE) | Baseline, at each scheduled treatment visit, and at 3 months post-treatment |
| Self-reported neurocognitive symptoms as measured by the Alertness Behavior Subscale of the Sickness Impact Profile | Baseline, at each scheduled treatment visit, and at 3 months post-treatment |
| Delirium and delirium symptoms by the NEECHAM Confusion Scale and Confusion Assessment Method (CAM) | Baseline, at each scheduled treatment visit, and at 3 months post-treatment |
Secondary
| Measure | Time frame |
|---|---|
| Mood State measured by the Profile of Mood States (POMS-SF) | Baseline, at each scheduled treatment visit, and at 3 months post-treatment |
| Overall quality of life measured using Cantril's Ladder | Baseline and 3 months post-treatment |
| Alcohol, tobacco, and drug use as measured by the Alcohol Use Disorders Identification Test (AUDIT) | Baseline |
| Hospitalizations, emergency department visits, and unscheduled clinic visits | At each scheduled treatment visit and 3 months post-treatment |
| Falls, injuries, and other complications | At each scheduled treatment visit and 3 months post-treatment |
| Coping measured by the Mini-Mental Adjustment to Cancer Scale (Mini-MAC) | Baseline and 3 months post-treatment |
| Premorbid intellectual functioning as measured by the North American Adult Reading Test (NAART) | Baseline |
| Functional status measured by the Duke Older Americans Resources and Services (OARS) Activities of Daily Living Scale | Baseline, at each scheduled treatment visit, and at 3 months post-treatment |
| Symptom prevalence and distress measured using the short form of the Memorial Symptom Assessment Scale (MSASSF) | Baseline, at each scheduled treatment visit, and at 3 months post-treatment |
Countries
United States
Outcome results
None listed